Skip to main content

Table 2 Effect differences (95% confidence interval) between treatments on exacerbation rate [13, 15, 19, 33,34,35,36,37,38,39,40,41,42]

From: Monoclonal antibodies in type 2 asthma: a systematic review and network meta-analysis

Treatment Placebo Benralizumab Lebrikizumab Dupilumab Mepolizumab Tralokinumab Reslizumab Tezepelumab
Placebo   0.485 (− 0.132, 1.080) 0.903 (− 0.278, 2.380 0.903 (− 0.571, 2.570) 0.485 (− 0.797, 1.750) 0.755 (− 0.933, 2.640) 0.589 (− 1.100, 2.280) 1.170 (− 0.678, 3.150)
Benralizumab −0.485 (− 1.080, 0.132)   0.445 (− 0.850, 1.870) 0.439 (− 1.120, 2.070) −0.019 (− 1.300, 1.380) 0.283 (− 1.490, 2.130) 0.100 (− 1.620, 1.870) 0.697 (− 1.170, 2.670)
Lebrikizumab −0.903 (− 2.380, 0.278) −0.445 (− 1.870, 0.850)   0.006 (− 1.950, 1.760) − 0.483 (− 2.110, 1.280) −0.172 (− 2.180, 1.920) −0.361 (− 2.390, 1.720) 0.258 (− 1.950, 2.460)
Dupilumab −0.903 (− 2.570, 0.571) −0.439 (− 2.070, 1.120) −0.006 (− 1.760, 1.950)   − 0.472 (− 2.330, 1.530) −0.164 (− 2.390, 2.160) −0.347 (− 2.430, 1.740) 0.258 (− 2.070, 2.760)
Mepolizumab −0.485 (− 1.750, 0.797) 0.019 (− 1.380, 1.300) 0.483 (− 1.280, 2.110) 0.472 (− 1.530, 2.330)   0.317 (− 1.750, 2.320) 0.122 (− 1.980, 2.150) 0.709 (− 1.580, 2.980)
Tralokinumab −0.755 (− 2.640, 0.933) − 0.283 (− 2.130, 1.490) 0.172 (− 1.920, 2.180) 0.164 (− 2.160, 2.390) −0.317 (− 2.320, 1.750)   − 0.188 (− 2.620, 2.230) 0.408 (− 2.000, 2.970)
Reslizumab − 0.589 (− 2.280, 1.100) −0.100 (− 1.870, 1.620) 0.361 (− 1.720, 2.390) 0.347 (− 1.740, 2.430) −0.122 (− 2.150, 1.980) 0.188 (− 2.230, 2.620)   0.604 (− 1.810, 3.090)
Tezepelumab −1.170 (− 3.150, 0.678) − 0.697 (− 2.670,1.170) −0.258 (− 2.460, 1.950) −0.258 (− 2.760,2.070) −0.709 (− 2.980, 1.580) −0.408 (− 2.970, 2.000) −0.604 (− 3.090, 1.810)  
  1. Table showing the effect differences detected between all agents compared to placebo, all effect differences were not statistically significant and had wide confidence intervals, and therefore no agents could prove superior to another. The studies on IL-5 pathway agents included patients with a relatively higher number of exacerbations, due to selecting patients with a history of exacerbations and documented eosinophilia, which should be taken into account when interpreting their compared effects. No agent could prove superior to another in these indirect head to head comparisons